The Patent Finder

Dendreon Pharmaceuticals LLC

Also on record
Records under this name other than the patents Dendreon Pharmaceuticals LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 8 patents it holds.

Back to Dendreon Pharmaceuticals LLC

PatentTitleStatus Expires Confidence
US 7,572,444Binding Proteins Specific for Human Matriptase
Term ended
Term ended Dec 16, 2025 · High confidence
Term endedTerm ended Dec 16, 2025High confidence
US RE43,298Peptides as NS3-SERINE Protease Inhibitors of Hepatitis C Virus
Formerly held
Term ended
Term ended Dec 22, 2024 · Low confidence
Term endedTerm ended Dec 22, 2024Low confidence
US 7,132,398Method of Treatment of Hemorrhagic Disease Using a Factor Viia/Tissue Factor Inhibitor
Term ended
Term ended Jan 29, 2024 · High confidence
Term endedTerm ended Jan 29, 2024High confidence
US 7,413,869Method for Determining Potency of Antigenic Presenting Cell Based Vaccines
Term ended
Term ended Nov 12, 2022 · High confidence
Term endedTerm ended Nov 12, 2022High confidence
US 6,962,795Neutrophil inhibitors
Term ended
Term ended Nov 8, 2022 · From the USPTO record
Term endedTerm ended Nov 8, 2022From the USPTO record
US 7,169,760Novel Peptides as NS3-SERINE Protease Inhibitors of Hepatitis C Virus
Formerly held
Term ended
Term ended Nov 6, 2022 · High confidence
Term endedTerm ended Nov 6, 2022High confidence
US 7,772,266Small-Molecule Modulators of TRP-P8 Activity
Lapsed on the fee record
Ended Aug 10, 2022 · High confidence
Lapsed on the fee recordEnded Aug 10, 2022High confidence
US 7,244,721Novel Peptides as NS3-SERINE Protease Inhibitors of Hepatitis C Virus
Term ended
Ended no later than Apr 15, 2022 · Medium confidence
Term endedEnded no later than Apr 15, 2022Medium confidence
US 8,658,177Promiscuous HER-2/Neu CD4 T cell epitopes
Lapsed on the fee record
Ended Feb 25, 2022 · From the USPTO record
Lapsed on the fee recordEnded Feb 25, 2022From the USPTO record
US 7,659,117Compositions and methods for dendritic cell-based immunotherapy
Lapsed on the fee record
Ended Feb 9, 2022 · From the USPTO record
Lapsed on the fee recordEnded Feb 9, 2022From the USPTO record
10 of 108 patents shown.
Pro members see all 108.
Pro members: see all 108 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited